Have a feature idea you'd love to see implemented?
Let us know!
COYA Coya Therapeutics Inc
Price (delayed)
$6.08
Market cap
$101.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.65
Enterprise value
$70.52M
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities,
Highlights
The company's quick ratio has surged by 122% YoY and by 40% QoQ
The EPS has surged by 69% year-on-year and by 11% since the previous quarter
COYA's net income is up by 13% YoY but it is down by 6% QoQ
The company's equity fell by 9% QoQ
Key stats
What are the main financial stats of COYA
Market
Valuations
Earnings
Shares outstanding
16.71M
Market cap
$101.58M
Enterprise value
$70.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.89
Price to sales (P/S)
9.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.38
Revenue
$9.55M
EBIT
-$9.98M
EBITDA
-$9.95M
Free cash flow
-$10.12M
Per share
Balance sheet
Liquidity
EPS
-$0.65
Free cash flow per share
-$0.66
Book value per share
$2.1
Revenue per share
$0.63
TBVPS
$2.34
Total assets
$35.55M
Total liabilities
$3.54M
Debt
$0
Equity
$32.01M
Working capital
$33.19M
Debt to equity
0
Current ratio
15.31
Quick ratio
13.39
Net debt/EBITDA
3.12
Margins
Efficiency
Dividend
EBITDA margin
-104.1%
Gross margin
100%
Net margin
-112%
Operating margin
-118.8%
Return on assets
-27.8%
Return on equity
-31.6%
Return on invested capital
-1,675.1%
Return on capital employed
-30%
Return on sales
-104.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COYA stock price
How has the Coya Therapeutics stock price performed over time
Intraday
0.83%
1 week
-10.72%
1 month
-26.48%
1 year
22.58%
YTD
-17.95%
QTD
-5.74%
Financial performance
How have Coya Therapeutics's revenue and profit performed over time
Revenue
$9.55M
Gross profit
$9.55M
Operating income
-$11.35M
Net income
-$10.7M
Gross margin
100%
Net margin
-112%
COYA's net income is up by 13% YoY but it is down by 6% QoQ
Coya Therapeutics's operating income has decreased by 8% from the previous quarter but it has increased by 3.1% YoY
Coya Therapeutics's operating margin has decreased by 8% from the previous quarter
Coya Therapeutics's net margin has decreased by 6% from the previous quarter
Growth
What is Coya Therapeutics's growth rate over time
Valuation
What is Coya Therapeutics stock price valuation
P/E
N/A
P/B
2.89
P/S
9.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.38
The EPS has surged by 69% year-on-year and by 11% since the previous quarter
The company's equity fell by 9% QoQ
The P/B is 3.7% below the last 4 quarters average of 3.0
COYA's P/S is 30% below its last 4 quarters average of 13.9
Efficiency
How efficient is Coya Therapeutics business performance
Coya Therapeutics's return on equity has surged by 80% YoY and by 11% QoQ
The ROA has soared by 71% YoY and by 10% from the previous quarter
The return on sales has declined by 6% since the previous quarter
Dividends
What is COYA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COYA.
Financial health
How did Coya Therapeutics financials performed over time
The company's total assets has surged by 199% YoY but it fell by 11% QoQ
COYA's current ratio has surged by 134% year-on-year and by 47% since the previous quarter
Coya Therapeutics's debt is 100% less than its equity
The company's equity fell by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.